Questions
CJC-1295 Ipamorelin: Questions and Cited Answers
Direct answers to the questions readers most often ask, attributed to single-component and synergy studies.
Is Ipamorelin stronger than Sermorelin?
They are not measured on the same axis. Ipamorelin's distinction is selectivity, not raw strength: it is the first selective GH secretagogue, not raising ACTH or cortisol above GHRH-stimulated levels even at more than 200 times the dose needed for half its GH effect, while matching GHRP-6's GH efficacy in swine [2]. Sermorelin is a short-acting GHRH peptide working through a different receptor entirely.
Does Ipamorelin make you hungry / increase appetite?
It can, mechanistically: ipamorelin acts on the ghrelin (hunger) receptor, and increased appetite after dosing is among the most frequently reported community effects — generally described as milder than with GHRP-6. This is anecdotal, not clinical evidence. The class safety review's chief documented concern is metabolic — raised blood glucose from decreased insulin sensitivity — not appetite [6].
Does Ipamorelin burn fat?
No controlled human trial shows ipamorelin burning fat. The closest cited evidence is for a different molecule, the GHRH analogue tesamorelin: a 2026 meta-analysis of five randomized trials found reduced visceral fat (−27.71 cm²) and liver fat (−4.28%) and increased lean mass (+1.42 kg) [7]. Community fat-loss reports for the stack are gradual, lifestyle-confounded, and anecdotal.
What is CJC-1295 / Ipamorelin good for?
In documented terms, each component reliably raises growth hormone: a single dose of CJC-1295 (DAC) raised GH two- to ten-fold for six or more days and IGF-1 for nine to eleven days in healthy adults [1], and ipamorelin releases GH cleanly without stress-hormone activation [2]. Downstream day-to-day benefits people report — sleep, recovery — are anecdotal, not proven for the blend.
What are the bad side effects of CJC-1295 and Ipamorelin?
Mechanistically expected effects of raising GH include fluid retention, carpal-tunnel-type tingling, joint aches, and raised blood glucose from reduced insulin sensitivity — the class's chief metabolic concern per a secretagogue safety review [6]. Community reports add injection-site reactions and a brief post-injection flush. The blend itself has no controlled-trial adverse-event record.
How long do CJC-1295 and Ipamorelin take to work?
Pharmacologically, the hormone response is fast and long. A single subcutaneous dose of CJC-1295 (DAC) raised GH for six or more days and IGF-1 for nine to eleven days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. Ipamorelin's GH peak comes near 40 minutes post-dose [8]. Reported subjective effects like sleep are described within one to two weeks, anecdotally.
How many mg of CJC-1295 and Ipamorelin should I take?
This site gives no human dose and no protocol. The literature records what was studied: 30 to 60 µg/kg subcutaneous for CJC-1295 (DAC) in human pharmacokinetic work [1], and rodent-only ipamorelin doses such as 100 µg/kg three times daily [11]. There is no validated human ipamorelin dose and no trial of the fixed combination. Dosing decisions are not addressed here.
Does CJC-1295 raise testosterone?
The literature here concerns the GH/IGF-1 axis, not testosterone. A single dose of CJC-1295 (DAC) raised GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults [1]; no testosterone elevation is established for CJC-1295 in this record. Claims of a direct testosterone effect are not supported by the cited studies.
Does Ipamorelin reduce belly fat?
No controlled human trial demonstrates ipamorelin reducing belly fat. The cited visceral-fat evidence belongs to the GHRH analogue tesamorelin, where a 2026 meta-analysis found a −27.71 cm² visceral-fat reduction across five randomized trials [7]. For ipamorelin specifically, belly-fat reduction is a community report, gradual and lifestyle-confounded — anecdotal, not clinical evidence.
What are the downsides to CJC-1295 / Ipamorelin?
The genuine downsides are the untested fixed blend, mismatched pharmacokinetics (a days-long agent paired with an hours-long one) [1] [2], no FDA approval, unverified research-grade purity, and the class glucose signal [6]. Reported nuisances include water retention, post-injection flushing, and injection-site reactions. The honest summary: documented single-component pharmacology, undocumented combination safety.
Which is better, Sermorelin or Ipamorelin?
There is no head-to-head trial, so "better" depends on the goal. Sermorelin is a short-acting GHRH peptide; ipamorelin is a selective ghrelin-receptor secretagogue [2] working through a different receptor. They are not substitutes for one another — in the combination, the CJC-1295 GHRH arm is the sermorelin-comparable piece, while ipamorelin adds a second, independent mechanism. Neither is FDA-approved as used here.
Can you take both Sermorelin and Ipamorelin together?
The general principle that a GHRH peptide and a GHRP can be combined is well established: in normal men, submaximal GHRP doses combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms [3]. That said, this site describes the published synergy, not a protocol — it does not advise combining or administering any compounds, and no trial of that specific pairing exists.
Is Tesamorelin better than Ipamorelin?
They do different jobs and are not directly comparable. Tesamorelin is a GHRH analogue with strong controlled human body-composition data — a 2026 meta-analysis of five trials found reduced visceral and liver fat and increased lean mass [7]. Ipamorelin is a selective ghrelin-receptor secretagogue [2] with no comparable controlled human body-composition trial. "Better" depends entirely on which mechanism and endpoint are in question.
Which is safer, Sermorelin or Ipamorelin?
No controlled head-to-head comparison exists, so safety cannot be ranked from the record. Both ultimately raise GH and therefore share the class signal — chiefly raised blood glucose from decreased insulin sensitivity, with long-term cancer and mortality data still needed [6]. Ipamorelin's selectivity (no stress-hormone activation) is a documented tolerability advantage over the older GHRPs [2], but that is a within-GHRP comparison, not a sermorelin one.
What is CJC-1295 / Ipamorelin?
It is a research combination of two peptides: CJC-1295, a long-acting GHRH analogue (with DAC, an albumin-binding feature giving it a multi-day half-life [5]), and ipamorelin, the first selective GH secretagogue acting on the ghrelin receptor [2]. Together they push two independent switches on the pituitary to raise growth-hormone release. Neither is FDA-approved, and the fixed blend has no controlled-trial record.
How much CJC-1295 / Ipamorelin should I take?
No human dosing is provided here. The published record contains research-context amounts only — for example, 30 to 60 µg/kg subcutaneous for CJC-1295 (DAC) in human PK studies [1], and rodent-only ipamorelin dosing [9] [11]. There is no validated human ipamorelin dose and no studied protocol for the combination, so this question is not answered with a number.
Is CJC-1295 / Ipamorelin safe?
There is no controlled human safety study of the fixed blend, so its safety is uncharacterized. The single components and their class were judged generally well tolerated in a secretagogue review, with raised blood glucose the chief concern and long-term cancer and mortality data still needed [6], and ipamorelin shows a clean selectivity profile [2]. Unverified purity and self-administration add further unstudied risk.
Does CJC-1295 / Ipamorelin work?
Each component demonstrably raises growth hormone: CJC-1295 (DAC) raised GH two- to ten-fold for six or more days and IGF-1 for nine to eleven days in healthy adults [1], and ipamorelin reliably releases GH [2]. Whether the combination produces the downstream day-to-day benefits people seek is not established by any controlled trial — those outcomes are extrapolated and anecdotal.
Is Ipamorelin FDA approved?
No. Ipamorelin is not approved by the FDA for any indication and is sold only as a research chemical, as is CJC-1295. A secretagogue safety review notes the class is generally well tolerated but emphasizes that long-term and large-population safety data remain lacking [6]. The fixed combination likewise holds no approval and has never been studied in a controlled human trial.
How to reconstitute CJC-1295 / Ipamorelin (5mg)?
This site does not provide reconstitution instructions. In a laboratory-handling context, lyophilized peptide is reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol), kept refrigerated at 2 to 8 °C, and protected from agitation and freeze-thaw because aqueous peptide degrades over weeks via deamidation. That is descriptive handling information for completeness, not a preparation protocol for use.
Where to inject CJC-1295 / Ipamorelin?
No injection instruction is given here. The literature records subcutaneous administration as the dominant route in the human CJC-1295 pharmacokinetic work [1] and most rodent ipamorelin studies, with intravenous and intranasal routes also studied [8]. Those are records of how studies were conducted, not directions for administering anything to a person.
Can I take CJC-1295 / Ipamorelin in the morning?
Timing is a dosing decision this site does not make. Mechanistically, the long-acting CJC-1295 (DAC) sustains GH and IGF-1 for days regardless of time of day [1], while ipamorelin produces a short pulse peaking near 40 minutes [8]; community accounts often favor a pre-bed pulse to align with sleep, but that is anecdotal preference, not a studied schedule, and no protocol is endorsed here.